Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada

Ciprofloxacin, the first fluoroquinolone to be used to treat lower respiratory tract infections (LRTI), demonstrates poor potency against Streptococcus pneumoniae, and its use has been associated with the emergence of resistance. During the last decade, fluoroquinolones with enhanced in vitro activi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Patel, Samir N., McGeer, Allison, Melano, Roberto, Tyrrell, Gregory J., Green, Karen, Pillai, Dylan R., Low, Donald E.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2011
Matèries:
Epidemiology and Surveillance
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3147653/
https://ncbi.nlm.nih.gov/pubmed/21628545
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00237-11
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars